Acute Hepatitis C in the PROUD pilot study
|
|
|
- Augustine Gordon
- 5 years ago
- Views:
Transcription
1 Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study
2 PROUD Pilot Study PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men
3 Background Pre-exposure prophylaxis (PrEP) has proven biological efficacy to reduce the sexual acquisition of HIV 1, but public health benefit is uncertain. Concerns about the effect of PrEP usage on risk behavior and acquisition of other STIs Excluding intravenous transmission, Hepatitis C (HCV) is almost exclusively found in HIV positive MSM. HCV testing is not routine in HIV negative MSM, so it is not included in the PROUD study 1.Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363: Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61:586-9
4 Methods Past history of STIs is collected at enrolment STI screens are conducted at six monthly intervals, but results from additional routine screens are collected at each visit (three monthly) HCV antibody and raised ALT were not exclusion criteria in PROUD Acute HCV defined as: HCV RNA positive and anti HCV negative (with follow up) HCV Ab/RNA positive with previous negative in 6 months
5 Results 393 participants enrolled by 31/12/ (41%) individuals had been tested on one or more occasion for HCV. HCV incidence in our cohort was 5/393:1.3%, and amongst those tested 5/160:3.1%.
6 Case characteristics Site Randomization ARM Age Time from enrolment to HCV diagnosis (Days) HCV RNA Baseline Indication for HCV Testing Symptoms/ ALT STI since enrolment Brighton Immediate Risk behaviour NO Yes Barts Immediate Partner HCV (+) NO No Manchester Deferred Symptoms Jaundice/ Raised ALT Yes STH Immediate Partner HCV (+) NO No KLC Deferred ,641,554 IDU NO Yes
7 Time since last HCV negative to HCV diagnosis Case #1 Case #2 Case #3 Case #4 Case #5 days -20 Screening -10 Randomization
8 Conclusions There was an unexpected number of ahcv cases. HIV prevention studies should consider including HCV testing at baseline and follow-up as part of testing for other STIs. Undiagnosed acute HCV infection in MSM reporting high risk sex is a public health concern. Routine testing of HCV and ALT in the list of routine STIs should be considered for this group.
9 Acknowledgements (1) Study participants MRC CTU at UCL David Dolling, David Dunn, Mitzy Gafos, Gemma Wood, Liz Brodnicki, Yolanda Collaco- Moraes, Sarah Banbury, Brendan Mauger, Yinka Sowunmi, Christina Chung, Monica Desai, Sheena McCormack HIV & STI Dept, PHE Anthony Nardone, Noel Gill, Sarika Desai, Monica Desai, GUMCAD team, HIV team Clinics Vanessa Apea (Barts Health NHS Trust), Nicola Mackie (St Mary s Hospital), Alan McOwan (56 Dean Street), Amanda Clarke (Claude Nichol Centre), Christine Bowman (Sheffield Teaching Hospitals NHS Foundation Trust), Charles Lacey (York Hospitals NHS Foundation Trust), Gabriel Schembri (Manchester Centre for Sexual Health), Richard Gilson (The Mortimer Market Centre), Ann Sullivan (John Hunter Clinic for Sexual Health), Iain Reeves (Homerton University Hospital NHS Foundation Trust), Michael Brady (Kings College Hospital NHS Foundation Trust), Julie Fox (Guy s and St Thomas s NHS Foundation Trust), Steve Taylor (Heart of England NHS Foundation Trust), Saye Khoo (University of Liverpool)
10 Acknowledgements (2) Trial Steering Committee Independent members: Mike Adler (Co-Chair), Gus Cairns (Co-Chair), Rob Cookson, Dan Clutterbuck, Claire Foreman, Matthew Williams, Stephen Nicholson, Tariq Sadiq Investigator members: Noel Gill, Anne Johnson, Andrew Phillips, Sheena McCormack, Brian Gazzard Community Engagement Group Clinics: Alan McOwan (56 Dean St), Mark Roche (Brighton) Social media: Darren Clapich (Grindr), Simon Johnson (Gaydar) Press: David Rowlands (Baseline), Robert Fieldhouse (Baseline), Chris O Connor (Baseline), Patrick Cash (QX) Community: Ben McClelland (THT), Matthew Hodson (GMFA), Cary James (THT), Tom Doyle (Mesmac), Yusef Azad (NAT), Justin Harbottle (THT), Roger Pebody (NAM) Academia: Will Nutland (LSHTM) MRC CTU at UCL: Sheena McCormack, Mitzy Gafos, Monica Desai, Annabelle South PHE: Francesa McNeil Gilead Jim Rooney, Rich Clarke, Matt Bosse, Murad Ruf
Professor Sheena McCormack
21 st Annual Conference of the British HIV Association (BHIVA) Professor Sheena McCormack MRC Clinical Trials Unit at UCL, London 21-24 April 2015, The Brighton Centre 21 st Annual Conference of the British
Dr Monica Desai. MRC Clinical Trials Unit at UCL, London. Science of PrEP. Monica Desai
8 th Annual Conference of the Children s HIV Association Closing the Gap: Treatment and Prevention Dr Monica Desai MRC Clinical Trials Unit at UCL, London 8 th Annual Conference, Friday 16 th May 2014
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: McCormack S, Dunn DT, Desai M, et al. Pre-exposure
National HIV self-sampling service. Luis E. Guerra National Programme Manager Sexual Health, Reproductive Health & HIV
National HIV self-sampling service Luis E. Guerra National Programme Manager Sexual Health, Reproductive Health & HIV Luis.Guerra@phe.gov.uk @ LGUERRAC Outlines Who is using the service? Is the service
Articles. Funding MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial Sheena McCormack*, David T Dunn*, Monica
Drug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
Dr Huw Price University College London
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Dr Huw Price University College London 6-8 April 2011, Bournemouth International Centre Hepatitis B virus co-infection in HIV-infected patients
Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late?
Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late? Thomas Martin, Sophie Jose, Alicia Thornton, Natasha Martin, Caroline Sabin, Mark Nelson Background Antiretroviral therapy (ART)
First-line NNRTI to second-line PI/r
Outcomes of 2 nd line ART First-line NNRTI to second-line PI/r Laura Waters, David Asboe,, Anton Pozniak, Loveleen Bansi, Chloe Orkin, Erasmus Smit, Esther Fearnhill & Andrew Phillips. UK Resistance Database
Baseline renal function is an independent predictor of death and progression to severe chronic kidney disease
Baseline renal function is an independent predictor of death and progression to severe chronic kidney disease Fowzia Ibrahim, Lisa Hamzah, Rachael Jones, Loveleen Bansi, Dorothea Nitsch, Caroline Sabin
PrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016
Dr Mags Portman Mortimer Market Centre, London Speaker Name Statement Dr Margaret Portman None Declared Date : September 2016 PrEP - Tackling Implementation Dr Mags Portman Mortimer Market Centre 15 th
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour
https://doi.org/10.1007/s10461-018-2300-5 ORIGINAL PAPER The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour Mitzy Gafos 1,2 Rob
Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities
Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities Professor Kevin Fenton Senior Advisor, Public Health England Director,
Met and unmet health, welfare and social needs of people accessing HIV services Findings from the Positive Voices 2017 survey
Met and unmet health, welfare and social needs of people accessing HIV services Findings from the Positive Voices 2017 survey Meaghan Kall Public Health England on behalf of the Positive Voices study group
HIV prevention: developments since 2012
HIV prevention: developments since 2012 9 May 2016 Yusef Azad, Director of Strategy, NAT Overview Developments in (our understanding of) the UK HIV epidemic Policy direction Changes in English health and
Professor Caroline Sabin
Professor Caroline Sabin in partnership with Royal Free & University College Medical School London, UK COMPETING INTEREST OF FINANCIAL VALUE > 1,000 Statement Over the past five years, Caroline Sabin has
UK clinicians approach to ART in primary HIV infection; comparison with the BHIVA guidelines
UK clinicians approach to ART in primary HIV infection; comparison with the BHIVA guidelines Dr. Julie Fox Victoria Parsons 1, Sarah Fidler 2, Naomi Fitzgerald 3, Simon Collins 4, Andrew Phillips 1, Richard
Sexualised drug use: the national picture. Dr Ellen Heinsbroek HIV & STI Dept, National Infection Service, Public Health England
Sexualised drug use: the national picture Dr Ellen Heinsbroek HIV & STI Dept, National Infection Service, Public Health England Overview What is chemsex? What is the prevalence of chemsex? Why does it
Harnessing molecular technology to inform our understanding of HIV and STI epidemics
NIHR Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections Harnessing molecular technology to inform our understanding of HIV and STI epidemics Katy Town PhD candidate Centre
CROI 2015: HIV Prevention Updates
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2015: HIV Prevention Updates Ruanne V Barnabas, MBChB Dphil Global Health and Medicine University of Washington a bevy of new studies quelled most remaining
National HIV self-sampling service
National HIV self-sampling service National HIV Prevention England Conference London, UK Presented by: Luis E. Guerra National Programme Manager Sexual Health, Reproductive Health & HIV Luis.Guerra@phe.gov.uk
Trends in transmitted drug resistance to HIV-1 in the UK since 2010
Trends in transmitted drug resistance to HIV-1 in the UK since 2010 Anna Tostevin, Ellen White, Sara Croxford, Valerie Delpech, Ian Williams, David Dunn on behalf of the UK HIV Drug Resistance Database
Using anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
HIV pre-exposure prophylaxis (PrEP)
BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018 Guideline writing group Michael Brady (Co-chair) Consultant in Sexual Health and HIV, King s College Hospital, London Alison
Government of Canada Federal AIDS Initiative Milestones
HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for
PrEP: Preexposure Prophylaxis to prevent HIV Lisa Pietrusza, BSN, RN FNP-DNP student, University of Pittsburgh Nov. 3, 2017.
PrEP: Preexposure Prophylaxis to prevent HIV Lisa Pietrusza, BSN, RN FNP-DNP student, University of Pittsburgh Nov. 3, 2017 Disclosures The views expressed heroine do not necessarily reflect the official
Suicide among people diagnosed with HIV in England and Wales compared to the general population
Suicide among people diagnosed with HIV in England and Wales compared to the general population Sara Croxford, Meaghan Kall, Fiona Burns, Andrew Copas, Alison Brown, Sarika Desai, Ann K Sullivan, Andrew
25th Annual Conference of the British HIV Association Bournemouth 2019
25th Annual Conference of the British HIV Association Bournemouth 2019 Declarations Dr Ming Lee has no conflicts of interests relevant to this presentation. Dr Ming Lee Dr David Chadwick In 2016 around
Downloaded from:
Lampe, F; Speakman, A; Sherr, L; Phillips, A; Collins, S; Gilson, R; Johnson, M; Fisher, M; Wilkins, E; Anderson, J; Daskalopoulou, M; Edwards, S; McDonnell, J; Perry, N; Jones, M; O Connell, R; Lascar,
emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd
emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of
HIV testing in England and the NICE Quality Standards
HIV testing in England and the NICE Quality Standards Dr Nicky Connor HIV & STI Department National Infection Service Public Health England December 2017 The continuum of HIV care by region of residence
HIV testing as the bridge between awareness and acceptance of PrEP among MSM
PA_3 #08 HIV testing as the bridge between awareness and acceptance of PrEP among MSM Tsz Ho Kwan, BSc, MIET PhD Candidate in Public Health 1 June 2017 Content Background HIV epidemiology in Hong Kong
HIV in primary care. How effective and safe are HIV testing and care in General Practice?
HIV in primary care How effective and safe are HIV testing and care in General Practice? Dr Werner Leber GP and Clinical Lecturer in Primary Care and Public Health Queen Mary, University of London werner.leber@nhs.net
The REACH project: Factors associated with intervals between women s visits to HIV outpatient clinics
The REACH project: Factors associated with intervals between women s visits to HIV outpatient clinics Dr Fiona Burns on behalf Dr Alison Evans and the REACH team Research Department of Infection and Population
Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know
Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know ANTONIO E. URBINA, MD Medical Director Associate Professor of Medicine Mt. Sinai Hospital Disclosure
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally
Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
Dr Anatole Menon-Johansson
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Anatole Menon-Johansson Guy s and St Thomas NHS Foundation Trust, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF
The HIV Prevention England programme: what s next? Cary James May 2016
The HIV Prevention England programme: what s next? Cary James May 2016 Summary Programme objectives Campaign evolution Sector development Structure and governance Support for HIV prevention system Communication
Arizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
Scaling up HIV PrEP: How HIV nurses knowledge, attitudes, and behaviors impact PrEP Implementation
Scaling up HIV PrEP: How HIV nurses knowledge, attitudes, and behaviors impact PrEP Implementation Jeffrey Kwong, DNP, MPH, ANP-BC, ACRN, FAANP Carole Treston, RN,MPH,ACRN, FAAN Jason Farley, PhD, MPH,ANP-BC,
Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Syphilis Key facts In 2015, 28 701 syphilis cases were reported in 29 EU/EEA Member States (data were not available from Austria and Liechtenstein),
South African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
Gabriel et al. BMC Infectious Diseases (2018) 18:531
Gabriel et al. BMC Infectious Diseases (2018) 18:531 https://doi.org/10.1186/s12879-018-3433-x STUDY PROTOCOL Open Access Protocol, rationale and design of SELPHI: a randomised controlled trial assessing
Increase in syphilis testing and detection of early syphilis among men who have sex with men across Australia
6//26 Increase in syphilis testing and detection of early syphilis among men who have sex with men across Australia 27-24 Eric P.F. Chow,2, Denton Callander 3,4, Christopher K Fairley,2, Lei Zhang,2, Basil
Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination
Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359
Combination HIV Prevention
Combination HIV Prevention The future of HIV services in England King s Fund Conference London 25 April 2017 Dr Anthony Nardone Microbicides for women Abdool Karim Q, Science 2010 Treatment for prevention
Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults
Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults Reference: NHS England F03X06 First published: TBC Prepared by NHS England Specialised
Public Health Interventions Advisory Committee (PHIAC)
Public Health Interventions Advisory Committee (PHIAC) PHIAC 48: Information, sun protection resources and environmental changes to prevent skin cancer Increasing the uptake of HIV testing among Africans
Time to Test for HIV
FINAL PROGRAMME on HIV Testing Mission Statement HIV remains a concern in the UK and expanding testing will result in earlier diagnosis with benefits to the individual as well as the population. This conference
Pre-exposure Prophylaxis. Robert M Grant October 2014
Pre-exposure Prophylaxis Robert M Grant October 2014 The HIV Pandemic 2.3 Million New HIV Infections in 2012 39% in Young People (ages 15-24) The HIV Pandemic 1.6 Million Started Therapy in 2012 1.4 New
UK CAB HIV treatment advocates network
UK CAB HIV treatment advocates network CAB 37: Treatment as prevention 04 February 2011 Contents: Members attending 2 Programme 3 Company pre-meeting Michael Marr 4 iprex Trial design; statistical aspect
PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
PrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
Incidence des IST chez les PrEPeurs
Incidence des IST chez les PrEPeurs Jean-Michel Molina Hopital Saint-Louis, Université de Paris Diderot, Inserm U941, Paris, France PrEP, IST et Santé Sexuelle, 29 Mars 2018, Paris La PrEP en France Début
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
BHIVA Satellite Symposium. Tougher Times: Adapting to Increasing Demand with Declining Resources
BHIVA Satellite Symposium Tougher Times: Adapting to Increasing Demand with Declining Resources Monday 24 July 2017 Dr Nneka Nwokolo 56 Dean Street, Chelsea and Westminster Hospital, London Speaker Name
and Future Directions
Involve[men]t PrEP, Health Disparities, A Study of Race and Age in HIV/STI Incidence and Prevalence Among MSM in Atlanta, and Future Directions GA: 2009-2014 Patrick Sullivan, DVM, PhD Rollins School of
Chlamydia Screening strategy in the UKhow far have we come?
Chlamydia Screening strategy in the UKhow far have we come? Dr Janette Clarke Chair, National Chlamydia Screening Advisory Group Department of Health England Jan.clarke@leedsth.nhs.uk 13/01/2010 National
Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013
Good care for people with HIV. Rights and Wrongs Jane Anderson May 2013 Recognition 1981-91 Intervention 1991-2001 Stabilisation 2001-2012 HIV in evolution Crisis management Palliative care Discovery Assessing
Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings
Implementing HIV Screening at Hub and Spoke Sites and Other Drug Treatment Settings Dennis Fleming, MA CDPH/Office of AIDS DHCS Statewide SUD Conference August 23, 2018 Anaheim, CA Agenda What s New in
Addressing STIs among MSM: A Clinical and Public Health Update
Addressing STIs among MSM: A Clinical and Public Health Update Kevin L. Ard, MD, MPH National LGBT Health Education Center, Fenway Institute Infectious Disease Division, Massachusetts General Hospital
Engaging Black Men Who have Sex with Men (BMSM) in Los Angeles in HIV Pre-Exposure Prophylaxis (PrEP) Nina Harawa, PhD, MPH Associate Professor
Engaging Black Men Who have Sex with Men (BMSM) in Los Angeles in HIV Pre-Exposure Prophylaxis (PrEP) Nina Harawa, PhD, MPH Associate Professor Conflict of Interest & Acknowledgements I have no conflicts
CATIE STATEMENT. on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV
CATIE STATEMENT on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV The consistent and correct use of oral Truvada as pre-exposure
Clinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org PRE-EXPOSURE PROPHYLAXIS Speaker: Antonia Urbina, MD 9/6/2017 Pre-Exposure Prophylaxis [video transcript] 1 00:00:07,480 --> 00:00:09,139 I mean we're
HIV in Primary Care Shared Care
Final Programme Second Joint Multidisciplinary Conference of BHIVA and RCGP HIV in Primary Care Shared Care Friday 9 September 2016 30 Euston Square, London This conference is sponsored by ViiV Healthcare
Why do we need PrEP? Gus Cairns Editor, NAM / Prevention coordinator, EATG Co-chair, PROUD Study
Why do we need PrEP? Gus Cairns Editor, NAM / www.aidsmap.com Prevention coordinator, EATG Co-chair, PROUD Study We are winning the fight against HIV Life expectancy in treated PWHIV is becoming normal
PrEP provision in healthcare settings: UK and France
PrEP provision in healthcare settings: UK and France Dr Michael Brady Kings College Hospital Terrence Higgins Trust London Content How to integrate PrEP provision into: Sexual health services General health
Pre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
DMRI Drug Misuse Research Initiative
DMRI Drug Misuse Research Initiative Executive Summary Pilot UK-Injectable Methadone Trial (Pilot UK-INJECT) Final Report, February 2003 Report prepared by: Nicky Metrebian & Gerry V Stimson and William
Guidelines for the sexual & reproductive health in PLWH: draft 2016 update
Guidelines for the sexual & reproductive health in PLWH: draft 2016 update Laura Waters Consultant GU/HIV Medicine Mortimer Market Centre, CNWL, London Content 1. An apology 2. Methods 3. Scope 4. Draft
HIV in the United Kingdom
HIV in the United Kingdom Valerie Delpech and Alison Brown on behalf of the HIV and AIDS Reporting Section National Infection Service Public Health England Released 15 December 2017 Undetectable=Untransmittable
PrEP: Getting to the Tipping Point
PrEP: Getting to the Tipping Point Harvey J Makadon, MD The National LGBT Health Education Center, The Fenway Institute Professor of Medicine, Harvard Medical School April 15, 2016 Continuing Medical Education
HIV Conference Reportback. Carla Gorton HIV, Viral Hepatitis, Sexual Health Coordinator Cairns Sexual Health Service
HIV Conference Reportback Carla Gorton HIV, Viral Hepatitis, Sexual Health Coordinator Cairns Sexual Health Service Social Research & Epidemiology PrEP Dr Jared Baeten Washington Divergent HIV rates
Pre-exposure Prophylaxis for HIV Prevention
Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended
In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies
In Silico Pharmacokinetic/Pharmacodynamic Simulation Of Long Acting Tenofovir Injectable Formulation For Pre-exposure Prophylaxis Strategies Paul Curley, Darren Moss, Rajith K R Rajoli, James Hobson, Caren
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
HIV pre-exposure prophylaxis (PrEP)
BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2017 Guideline writing group Michael Brady (co-chair) Consultant in Sexual Health & HIV, King s College Hospital Alison Rodger (co-chair)
PrEP Home Checklist v1.0
PrEP Home Checklist v1.0 Every Visit o Risk Reduction Counseling o Appropriate referrals and follow-ups (SW, Pharmacy, et al.) o For those on PrEP: o Assessment of PrEP adherence, side effects, ongoing
BHIVA Best of CROI Feedback Meetings BHIVA Best of CROI Feedback Meetings 2012
BHIVA Best of CROI Feedback Meetings London North East England North West England Edinburgh Birmingham BHIVA Best of CROI Feedback Meetings 2012 Introduction Simon Collins HIV i-base 1 Community perspectives
Pre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018
Pre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018 Disclosures I have no financial disclosures to report Objectives Identify the need for HIV prevention
HIV transmission in the UK within Black African communities: how common is it and how do we prevent it? Dr Valerie Delpech
HIV transmission in the UK within Black African communities: how common is it and how do we prevent it? Dr Valerie Delpech We gratefully acknowledge persons living with HIV, clinicians, health advisors,
London Chemsex Network Scoping meeting January 2017
London Chemsex Network Scoping meeting January 2017 Who are we? London Friend since 1972 Health & well-being Coming out, social groups, activity groups Mental health counselling Sexual health & HIV Prevention
NYS PrEP Programming. Lyn Stevens, NP, MS, ACRN Office of the Medical Director, AIDS Institute PrEP Monitoring in NYC and NYS February 19, 2016
NYS PrEP Programming March 21, 2016 Lyn Stevens, NP, MS, ACRN Office of the Medical Director, AIDS Institute PrEP Monitoring in NYC and NYS February 19, 2016 March 21, 2016 2 New York State Priorities
THIRD JOINT CONFERENCE OF BHIVA AND BASHH Dr Jamie Frankis. Glasgow Caledonian University. 1-4 April 2014, Arena and Convention Centre Liverpool
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Jamie Frankis Glasgow Caledonian University 1-4 April 2014, Arena and Convention Centre Liverpool Understanding the acceptability of pre-exposure prophylaxis
The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence
Modelling HIV Transmission and Treatment for US MSM to Estimate the Impact of HPTN 078 on HIV Incidence Kate Mitchell, PhD Imperial College London London, UK 14 th June 2016 Introduction: HPTN 078 Enhancing
Q and A - the PARTNER Study: new results from PARTNER 2
Q and A - the PARTNER Study: new results from PARTNER 2 1. Study results What is the PARTNER Study? The PARTNER study is an international two-phase study that looked at whether HIV transmission occurs
Dr Melanie Rosenvinge
18 th Annual Conference of the British HIV Association (BHIVA) Dr Melanie Rosenvinge St George s Hospital NHS Trust, London 1820 April 2012, The International Convention Centre, Birmingham A multicentre
Boston EMA Ryan White Part A Integrated HIV Prevention and Care Plan. September 8 th, 2016
Boston EMA Ryan White Part A 2017-2021 Integrated HIV Prevention and Care Plan September 8 th, 2016 Presentation Overview Purpose of the Integrated Prevention and Care Plan Process of Developing the Plan
Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study
Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study Narat Punyacharoensin, William John Edmunds, Daniela De Angelis,
PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation. Part 1
The Elton John Centre Sussex House 1 Abbey Road Brighton BN2 1ES Tel 01273 523079 Fax 01273 523080 PARTICIPANT INFORMATION SHEET AND CONSENT FORM PrEP Impact Trial: A Pragmatic Health Technology Assessment
HIV in London: A Complexity Challenge
HIV in London: A Complexity Challenge Professor Jane Anderson (Homerton University Hospital) and Dr David Asboe (Chelsea and Westminster Hospital) NHS England Clinical Reference Group for HIV Representatives
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
Population-based PrEP implementation in NSW, Australia
Population-based PrEP implementation in NSW, Australia Andrew Grulich HIV Epidemiology and Prevention Program, Kirby Institute, UNSW Australia Second Asia Pacific AIDS and Co-infections Conference, Hong
Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
On the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council